Legis Daily

NIH Clinical Trial Diversity Act of 2023

USA118th CongressS-1701| Senate 
| Updated: 5/18/2023
Robert Menendez

Robert Menendez

Democratic Senator

New Jersey

Cosponsors (2)
Kirsten E. Gillibrand (Democratic)Susan M. Collins (Republican)

Health, Education, Labor, and Pensions Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
NIH Clinical Trial Diversity Act of 2023 This bill sets out requirements to increase the diversity of clinical trial participants. The bill also requires other activities to foster participation in clinical trials. As a condition of funding from the National Institutes of Health (NIH) for a clinical trial investigating a drug or device, a sponsor's application must include certain information related to diversity in its trial, such as goals for recruiting and retaining trial participants and plans for achieving the recruitment and retention goals and implementing less-burdensome clinical trial follow-up requirements. A sponsor must also annually share demographic data of clinical trial participants with the NIH. Further, the NIH and the Food and Drug Administration must carry out a national campaign to increase awareness about the need for diverse clinical trials.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

S 117-5268
NIH Clinical Trial Diversity Act of 2022
May 18, 2023
Introduced in Senate
May 18, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 19, 2023

Latest Companion Bill Action

HR 118-3503
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    S 117-5268
    NIH Clinical Trial Diversity Act of 2022


  • May 18, 2023
    Introduced in Senate


  • May 18, 2023
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.


  • May 19, 2023

    Latest Companion Bill Action

    HR 118-3503
    Referred to the Subcommittee on Health.

Health

NIH Clinical Trial Diversity Act of 2023

USA118th CongressS-1701| Senate 
| Updated: 5/18/2023
NIH Clinical Trial Diversity Act of 2023 This bill sets out requirements to increase the diversity of clinical trial participants. The bill also requires other activities to foster participation in clinical trials. As a condition of funding from the National Institutes of Health (NIH) for a clinical trial investigating a drug or device, a sponsor's application must include certain information related to diversity in its trial, such as goals for recruiting and retaining trial participants and plans for achieving the recruitment and retention goals and implementing less-burdensome clinical trial follow-up requirements. A sponsor must also annually share demographic data of clinical trial participants with the NIH. Further, the NIH and the Food and Drug Administration must carry out a national campaign to increase awareness about the need for diverse clinical trials.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

S 117-5268
NIH Clinical Trial Diversity Act of 2022
May 18, 2023
Introduced in Senate
May 18, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 19, 2023

Latest Companion Bill Action

HR 118-3503
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    S 117-5268
    NIH Clinical Trial Diversity Act of 2022


  • May 18, 2023
    Introduced in Senate


  • May 18, 2023
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.


  • May 19, 2023

    Latest Companion Bill Action

    HR 118-3503
    Referred to the Subcommittee on Health.
Robert Menendez

Robert Menendez

Democratic Senator

New Jersey

Cosponsors (2)
Kirsten E. Gillibrand (Democratic)Susan M. Collins (Republican)

Health, Education, Labor, and Pensions Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted